Novel therapeutic targets in Waldenstrom macroglobulinemia

Ansell, 2010, Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines, Mayo Clin Proc Mayo Clin, 85, 824, 10.4065/mcp.2010.0304 Treon, 2009, Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180, J Clin Oncol Off J Am Soc Clin Oncol, 27, 3830, 10.1200/JCO.2008.20.4677 Treon, 2015, Ibrutinib in previously treated Waldenstrom's macroglobulinemia, N Engl J Med, 372, 1430, 10.1056/NEJMoa1501548 Ngo, 2011, Oncogenically active MYD88 mutations in human lymphoma, Nature, 470, 115, 10.1038/nature09671 Lin, 2010, Regulation of adaptive immunity by the innate immune system, Science, 327, 291, 10.1126/science.1183021 Lin, 2010, Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling, Nature, 465, 885, 10.1038/nature09121 Treon, 2012, MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia, N Engl J Med, 367, 826, 10.1056/NEJMoa1200710 Ansell, 2014, Activation of TAK1 by MYD88 L265P drives malignant B-cell growth in non-Hodgkin lymphoma, Blood Cancer J, 4, 10.1038/bcj.2014.4 Liu, 2016, Targeting myddosome assembly in Waldenstrom macroglobulinaemia, Br J Haematol, 10.1111/bjh.14103 Loiarro, 2013, Targeting the Toll-like receptor/interleukin 1 receptor pathway in human diseases: rational design of MyD88 inhibitors, Clin Lymphoma Myeloma Leuk, 13, 222, 10.1016/j.clml.2013.02.003 Nelde, 2015, Identification and characterization of HLA class I-restricted MYD88 L265P-derived peptides as tumor-specific targets for immunotherapy, Blood, 126, 2750, 10.1182/blood.V126.23.2750.2750 Kelly, 2015, Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy, J Exp Med, 212, 2189, 10.1084/jem.20151074 Yang, 2013, A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia, Blood, 122, 1222, 10.1182/blood-2012-12-475111 Vajda, 2015, Abstract 785: IRAK4 inhibitors display synergistic activity when combined with BTK or PI3K inhibitors in B cell lymphomas, Cancer Res, 75, 785, 10.1158/1538-7445.AM2015-785 Mocsai, 2010, The SYK tyrosine kinase: a crucial player in diverse biological functions, Nat Rev Immunol, 10, 387, 10.1038/nri2765 Geahlen, 2014, Getting Syk: spleen tyrosine kinase as a therapeutic target, Trends Pharmacol Sci, 35, 414, 10.1016/j.tips.2014.05.007 Cheng, 2014, BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity, Leukemia, 28, 649, 10.1038/leu.2013.358 Hashimoto, 1998, Involvement of guanosine triphosphatases and phospholipase C-gamma2 in extracellular signal-regulated kinase, c-Jun NH2-terminal kinase, and p38 mitogen-activated protein kinase activation by the B cell antigen receptor, J Exp Med, 188, 1287, 10.1084/jem.188.7.1287 Suzuki, 2003, PI3K and Btk differentially regulate B cell antigen receptor-mediated signal transduction, Nat Immunol, 4, 280, 10.1038/ni890 Kuiatse, 2015, Targeting the spleen tyrosine kinase with fostamatinib as a strategy against Waldenstrom macroglobulinemia, Clin Cancer Res, 21, 2538, 10.1158/1078-0432.CCR-14-1462 Argyropoulos, 2016, Clonal B cells in Waldenstrom's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling, Leukemia, 30, 1116, 10.1038/leu.2016.8 McCubrey, 2007, Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance, Biochim Biophys Acta, 1773, 1263, 10.1016/j.bbamcr.2006.10.001 Bollag, 2012, Vemurafenib: the first drug approved for BRAF-mutant cancer, Nat Rev Drug Discov, 11, 873, 10.1038/nrd3847 Lugowska, 2015, Trametinib: a MEK inhibitor for management of metastatic melanoma, Onco Targets Ther, 8, 2251 Heuck, 2016, Inhibiting MEK in MAPK pathway-activated myeloma, Leukemia, 30, 976, 10.1038/leu.2015.208 Chitta, 2013, Development and characterization of a novel human Waldenstrom macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute – Waldenstrom macroglobulinemia 1, Leuk Lymphoma, 54, 387, 10.3109/10428194.2012.713481 Paulus, 2015, Silico modeling of oncogenic drivers in Waldenstrom macroglobulinemia to assess additional therapeutic targets within the BCR signaling pathway identifies MEK1/2 as a target: potential therapeutic role of binimetinib, Blood, 126, 1279, 10.1182/blood.V126.23.1279.1279 Palazzo, 2000, Centrosome maturation, Curr Top Dev Biol, 49, 449, 10.1016/S0070-2153(99)49021-0 Mahen, 2012, Pattern formation in centrosome assembly, Curr Opin Cell Biol, 24, 14, 10.1016/j.ceb.2011.12.012 Friedberg, 2014, Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas, J Clin Oncol Off J Am Soc Clin Oncol, 32, 44, 10.1200/JCO.2012.46.8793 Doudican, 2015, Personalization of cancer treatment using predictive simulation, J Transl Med, 13, 43, 10.1186/s12967-015-0399-y Paulus, 2015, Aurora kinase is a therapeutic target in ibrutinib-resistant Waldenstrom macroglobulinemia: in-silico target identification and in-vitro validation, Blood, 126, 2754, 10.1182/blood.V126.23.2754.2754 Adams, 2003, The proteasome: structure, function, and role in the cell, Cancer Treat Rev, 29, 3, 10.1016/S0305-7372(03)00081-1 Treon, 2007, Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248, Clin Cancer Res, 13, 3320, 10.1158/1078-0432.CCR-06-2511 Ghobrial, 2010, Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia, J Clin Oncol Off J Am Soc Clin Oncol, 28, 1422, 10.1200/JCO.2009.25.3237 D'Arcy, 2011, Inhibition of proteasome deubiquitinating activity as a new cancer therapy, Nat Med, 17, 1636, 10.1038/nm.2536 Tian, 2014, A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance, Blood, 123, 706, 10.1182/blood-2013-05-500033 Chitta, 2015, Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenstrom macroglobulinaemia tumour cells, Br J Haematol, 169, 377, 10.1111/bjh.13304 Paulus, 2015, Identification of USP14 and UCHL5 as druggable oncotargets in ibrutinib-resistant mantle cell lymphoma, Blood, 126, 1557, 10.1182/blood.V126.23.1557.1557 D'Arcy, 2012, Proteasome deubiquitinases as novel targets for cancer therapy, Int J Biochem Cell Biol, 44, 1729, 10.1016/j.biocel.2012.07.011 Paulus, 2015, VLX1570, a first in class Dub inhibitor, modulates BCR signaling and CXCR4 expression and demonstrates significant in vivo antitumor activity in a murine model of human Waldenstrom macroglobulinemia, Blood, 126, 703, 10.1182/blood.V126.23.703.703 Wang, 2014, Toll-like receptors and cancer: MYD88 mutation and inflammation, Front Immunol, 5, 367, 10.3389/fimmu.2014.00367 Lim, 2013, Abstract 2332: oncogenic MYD88 mutants require Toll-like receptors, Cancer Res, 73, 2332, 10.1158/1538-7445.AM2013-2332 Paulus, 2014, Therapeutic sensitivity of CD20- Waldenströms macroglobulinemia cells is determined by underlying genomic and epigenetic events, Blood, 124, 3115, 10.1182/blood.V124.21.3115.3115 Thomas, 2015, Preliminary results from a phase 1/2, open-label, dose-escalation clinical trial of IMO-8400 in patients with relapsed or refractory Waldenstrom's macroglobulinemia, Blood, 126, 1540, 10.1182/blood.V126.23.1540.1540 Bryan, 2015, Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy, Blood Rev, 29, 25, 10.1016/j.blre.2014.09.004 Medina, 2016, PD-1 pathway inhibitors: immuno-oncology agents for restoring antitumor immune responses, Pharmacotherapy, 36, 317, 10.1002/phar.1714 Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N Engl J Med, 372, 311, 10.1056/NEJMoa1411087 Ansell, 2014, PD-1 is expressed on B-cells in Waldenstrom macroglobulinemia and promotes malignant cell viability and proliferation, Blood, 124, 3015, 10.1182/blood.V124.21.3015.3015 Malavasi, 2008, Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology, Physiol Rev, 88, 841, 10.1152/physrev.00035.2007 van de Donk, 2016, Monoclonal antibodies targeting CD38 in hematological malignancies and beyond, Immunol Rev, 270, 95, 10.1111/imr.12389 Malavasi, 2011, CD38 and chronic lymphocytic leukemia: a decade later, Blood, 118, 3470, 10.1182/blood-2011-06-275610 Jiang, 2016, SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide, Leukemia, 30, 399, 10.1038/leu.2015.240 Sondergeld, 2015, Monoclonal antibodies in myeloma, Clin Adv Hematol Oncol, 13, 599 Rajkumar, 2016, Daratumumab in multiple myeloma, Lancet, 387, 1490, 10.1016/S0140-6736(15)01226-X Paulus, 2015, Immunophenotyping of Waldenstroms macroglobulinemia cell lines reveals distinct patterns of surface antigen expression: potential biological and therapeutic implications, PloS One, 10, 10.1371/journal.pone.0122338 Scheuermann, 1995, CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy, Leuk Lymphoma, 18, 385, 10.3109/10428199509059636 Maude, 2015, CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia, Blood, 125, 4017, 10.1182/blood-2014-12-580068 Smith, 2014, A systemic xenograft model of Waldenström's macroglobulinemia demonstrates the potent anti-tumor effect of second generation CD19 directed chimeric antigen receptor modified T cells in this disease, Blood, 124, 4484, 10.1182/blood.V124.21.4484.4484 Das, 2015, Selective inhibitors of nuclear export (SINE) in hematological malignancies, Exp Hematol Oncol, 4, 7, 10.1186/s40164-015-0002-5 Puente, 2011, Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia, Nature, 475, 101, 10.1038/nature10113 Tai, 2014, CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications, Leukemia, 28, 155, 10.1038/leu.2013.115 Gutierrez, 2013, Anti tumor activity of selinexor (KPT-330), a first-in-class oral selective inhibitor of nuclear export (SINE) XPO1/CRM1 antagonist in patients (pts) with relapsed/refractory multiple myeloma (MM) or Waldenstrom's macroglobulinemia (WM), Blood, 122, 1942 Treon, 2014, Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's macroglobulinemia, Blood, 124, 503, 10.1182/blood-2014-03-566273 Siegel, 2014, Updated results from a multicenter, open-label, dose-escalation phase 1b/2 study of single-agent oprozomib in patients with Waldenström macroglobulinemia (WM), Blood, 124, 1715, 10.1182/blood.V124.21.1715.1715 Tam, 2015, The BTK inhibitor, Bgb-3111, is safe, tolerable, and highly active in patients with relapsed/refractory B-cell malignancies: initial report of a phase 1 first-in-human trial, Blood, 126, 832, 10.1182/blood.V126.23.832.832 Byrd, 2016, Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia, N Engl J Med, 374, 323, 10.1056/NEJMoa1509981 Advani, 2011, Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia, Expert Opin Drug Metab Toxicol, 7, 765, 10.1517/17425255.2011.579105 O'Brien, 2007, Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia, J Clin Oncol Off J Am Soc Clin Oncol, 25, 1114, 10.1200/JCO.2006.07.1191 Chanan-Khan, 2009, Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma, Leuk Lymphoma, 50, 559, 10.1080/10428190902748971 Roberts, 2016, Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia, N Engl J Med, 374, 311, 10.1056/NEJMoa1513257 Paulus, 2014, AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenstrom macroglobulinaemia, Br J Haematol, 164, 352, 10.1111/bjh.12633 Gerecitano, 2015, A phase 1 study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma, Blood, 126, 254, 10.1182/blood.V126.23.254.254